Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF1
NCT06188741Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2025
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by University of Alabama at Birmingham. Started Aug 2025; status: recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT06188741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188741.